Welcome to our dedicated page for BioCryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.
BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.
The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.
In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.
BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.
For more information, please visit www.biocryst.com or follow them on LinkedIn.
BioCryst Pharmaceuticals (BCRX) will present four abstracts, including a Distinguished Industry Oral Abstract, at the American College of Allergy, Asthma & Immunology (ACAAI) meeting from November 4-8, 2021, in New Orleans. The presentations will focus on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment. Key findings include low HAE attack rates in patients and high patient satisfaction when switching from injectables to ORLADEYO. The company continues to support the transition to oral prophylactic treatments for HAE.
BioCryst Pharmaceuticals (BCRX) announced plans to report its third quarter 2021 financial results on November 3, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the call via phone or a live webcast on the company’s website. BioCryst focuses on discovering novel, oral medications for rare diseases, with products like ORLADEYO approved in multiple regions and ongoing development programs for other treatments, including BCX9930 and BCX9250.
BioCryst Pharmaceuticals (BCRX) has granted inducement options to nine new employees for a total of 178,500 shares of its common stock as of September 30, 2021. The options have an exercise price of $14.37 per share, matching the stock's closing price on that date. Vesting occurs in four equal installments annually, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and supports BioCryst's commitment to attracting talent in the rare disease treatment sector.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 2021 Cantor Virtual Healthcare Conference on September 28, 2021, at 2:00 p.m. ET. Investors can access the live audio webcast and replay on the company's website. BioCryst specializes in developing novel oral medicines for rare diseases, with approved products such as ORLADEYO® for certain medical conditions. The company is also working on several other treatments, including BCX9930 for complement-mediated diseases and galidesivir for viral infections.
BioCryst Pharmaceuticals (Nasdaq:BCRX) has appointed Dr. Amy McKee to its board of directors, enhancing its regulatory expertise. Dr. McKee, a former deputy center director at the FDA's Oncology Center of Excellence, brings over a decade of experience in drug development and regulatory strategy. She will aid in advancing the company's pivotal trials for BCX9930, aimed at treating PNH and other complement-mediated diseases. This strategic move is expected to strengthen BioCryst's leadership as it continues to develop innovative treatments for rare diseases.
On September 15, 2021, BioCryst Pharmaceuticals (BCRX) announced that the UK's NICE recommended ORLADEYO® (berotralstat) for preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older with at least two attacks per month. This marks the first oral, once-daily therapy for routine prevention of HAE attacks in these regions. The recommendation follows a successful Phase 3 trial, which showed an 80% average reduction in attack rates over time. ORLADEYO is already approved in the US and other regions, with further assessments expected in Scotland.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that the UAE's Ministry of Health has granted marketing authorization for ORLADEYO (berotralstat), designed to prevent recurrent attacks in patients aged 12 and older suffering from hereditary angioedema. This approval marks a significant advancement in treatment options for these patients. BioCryst has partnered with NewBridge Pharmaceuticals for distribution across the Gulf Cooperation Council (GCC) and Iraq, aiming to enhance market access for this innovative therapy.
BioCryst Pharmaceuticals (BCRX) will present at the 2021 Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 p.m. ET. Additionally, they will showcase their presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand starting September 13, 2021, at 7:00 a.m. ET. Investors can access the live audio webcast and replays on BioCryst's website. The company focuses on developing oral medicines for rare diseases and has several products approved or in development, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options to 18 new employees. The options allow the purchase of 199,000 shares at an exercise price of $15.92 and $16.15, corresponding to the closing stock prices on August 31 and September 1, 2021, respectively.
The options will vest in four equal annual installments, starting one year after the grant date, and are part of the Inducement Equity Incentive Plan, valid for 10 years.
BioCryst Pharmaceuticals (BCRX) announced the U.S. Department of Health and Human Services (HHS) has ordered an additional 10,000 doses of its antiviral influenza therapy, RAPIVAB, for approximately $7 million. This purchase will bolster the Strategic National Stockpile as part of a $34.7 million contract from 2018 to supply up to 50,000 doses over five years. With this order, BioCryst will have delivered 40,000 doses, enhancing preparedness for the upcoming influenza season. RAPIVAB is approved for treating acute uncomplicated influenza in patients over six months old.
FAQ
What is the current stock price of BioCryst Pharmaceuticals (BCRX)?
What is the market cap of BioCryst Pharmaceuticals (BCRX)?
What is BioCryst Pharmaceuticals' main product?
Where is BioCryst Pharmaceuticals headquartered?
What therapeutic areas does BioCryst Pharmaceuticals focus on?
What recent achievements has BioCryst Pharmaceuticals reported?
How does ORLADEYO® work?
What is the pipeline of BioCryst Pharmaceuticals?
Who are BioCryst Pharmaceuticals' partners?
What is the company's approach to drug development?
What are some of the challenges BioCryst Pharmaceuticals addresses?
How can I stay updated on BioCryst Pharmaceuticals' latest news?
